Oregon Medicaid targets expensive hepatitis drug

Published



WILSONVILLE, Ore. (AP) — An Oregon Medicaid committee on Thursday significantly scaled back access to an effective — but expensive — new drug used to treat hepatitis C.

The decision allows only a narrow set of Medicaid patients to be treated with the $1,000-per-pill drug known as Sovaldi, made by Gilead Sciences Inc.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.